Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000293)
SBP Name	Macrocyclic peptide Octreotide
Synonyms	CHIP-1; Octreotida; Octreotidum; Octrotide; Bynfezia?; Mycapssa?; Sandostatin?
Molecular Weight	1.0 kDa
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status	Marketed
PDB ID	6VC1
Sequence Length	7
SBP Sequence	>Macrocyclic peptide Octreotide [d-Phe]-Cys-Phe-[d-Trp]-Lys-Thr-Cys-NH-CH(CH2OH)-CH(OH)-CH3 > >Cys and Cys form disulfide bonds.
Sequence Description	Cys I and Cys II form disulfide bonds.
3D Structure
	Experimentally Validated Structure
	Click to Save PDB File

Protein Scaffold Information of This SBP
Scaffold ID	PS044 Scaffold Info	[1]
Scaffold Name	Macrocyclic peptide
Scaffold Class	Non-Antibody
Fold Type	Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
Somatostatin receptor type 1	BTS Info	Inhibitor	Acute pancreatitis [ICD-11: DC31.Z]; Acute and delayed intestinal radiation injury; Pancreatic fistula; Neuroendocrine tumour [ICD-11: XH8DS0]; Acromegaly [ICD-11: 5A60.0]; Polycystic liver disease [ICD-11: DB99.10]	N.A.	Novartis; Sandoz International GmbH	[1]

Clinical Trial Information of This SBP
NCT00001860	Click to show the Detail
Indication	Acromegaly; Pituitary Neoplasm
Phase	Phase II
Title	Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
Status	Completed
Sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00002252	Click to show the Detail
Indication	Diarrhea; HIV Infections
Phase	Not Applicable
Title	A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
Status	Completed
Sponsor	Sandoz
NCT00002253	Click to show the Detail
Indication	Diarrhea; HIV Infections
Phase	Not Applicable
Title	A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
Status	Completed
Sponsor	Sandoz
NCT00002779	Click to show the Detail
Indication	Lymphoma
Phase	Phase II
Title	Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Status	Completed
Sponsor	Alliance for Clinical Trials in Oncology
NCT00002864	Click to show the Detail
Indication	Breast Cancer
Phase	Phase III
Title	Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Status	Completed
Sponsor	NCIC Clinical Trials Group
NCT00002947	Click to show the Detail
Indication	Brain and Central Nervous System Tumors; Childhood Langerhans Cell Histiocytosis; Gastrointestinal Carcinoid Tumor; Head and Neck Cancer; Intraocular Melanoma; Islet Cell Tumor; Kidney Cancer; Lung Cancer; Melanoma (Skin); Neoplastic Syndrome; Neuroendocrine Carcinoma of the Skin; Pheochromocytoma
Phase	Phase I
Title	Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Status	Terminated
Sponsor	Yale University
NCT00002967	Click to show the Detail
Indication	Breast Cancer
Phase	Phase III
Title	Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
Status	Completed
Sponsor	NSABP Foundation Inc
NCT00003057	Click to show the Detail
Indication	Colorectal Cancer; Diarrhea
Phase	Phase III
Title	Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Status	Completed
Sponsor	Eastern Cooperative Oncology Group
NCT00003283	Click to show the Detail
Indication	Thymoma and Thymic Carcinoma
Phase	Phase II
Title	Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Status	Completed
Sponsor	Eastern Cooperative Oncology Group
NCT00004327	Click to show the Detail
Indication	Hereditary Hemorrhagic Telangiectasia; Ectasia
Phase	Phase II
Title	Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia
Status	Completed
Sponsor	National Center for Research Resources (NCRR)
NCT00004895	Click to show the Detail
Indication	Colorectal Cancer; Constipation, Impaction, and Bowel Obstruction; Extrahepatic Bile Duct Cancer; Gastric Cancer; Gastrointestinal Stromal Tumor; Nausea and Vomiting; Ovarian Cancer; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Phase	Phase II
Title	Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Status	Completed
Sponsor	Northwestern University
NCT00005906	Click to show the Detail
Indication	Lymphangioleiomyomatosis; Lymphangiomyomas; Pleural Effusions; Ascites
Phase	Phase II
Title	Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Status	Completed
Sponsor	National Heart, Lung, and Blood Institute (NHLBI)
NCT00006269	Click to show the Detail
Indication	Colorectal Cancer; Diarrhea
Phase	Phase III
Title	Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Status	Terminated
Sponsor	Novartis
NCT00006370	Click to show the Detail
Indication	Breast Cancer; Lung Cancer
Phase	Phase II
Title	Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00008073	Click to show the Detail
Indication	Unspecified Adult Solid Tumor, Protocol Specific
Phase	Phase I
Title	Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
Status	Completed
Sponsor	University of Pittsburgh
NCT00033605	Click to show the Detail
Indication	Cervical Cancer; Colorectal Cancer; Diarrhea; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific; Vaginal Cancer; Vulvar Cancer
Phase	Phase III
Title	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Status	Completed
Sponsor	Alliance for Clinical Trials in Oncology
NCT00049023	Click to show the Detail
Indication	Brain and Central Nervous System Tumors; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neuroblastoma; Pheochromocytoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Phase	Phase I
Title	Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Status	Completed
Sponsor	O'Dorisio, M S
NCT00050635	Click to show the Detail
Indication	Neoplasms; Diarrhea
Phase	Phase IV
Title	STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00068029	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Pegvisomant And Sandostatin LAR Combination Study
Status	Completed
Sponsor	Pfizer
NCT00068042	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Status	Completed
Sponsor	Pfizer
NCT00075868	Click to show the Detail
Indication	Anal Cancer; Colorectal Cancer; Drug/Agent Toxicity by Tissue/Organ; Radiation Enteritis
Phase	Phase III
Title	Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Status	Completed
Sponsor	Radiation Therapy Oncology Group
NCT00076362	Click to show the Detail
Indication	Obesity
Phase	Phase IV
Title	Pediatric Hypothalamic Obesity
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00088582	Click to show the Detail
Indication	Acromegaly
Phase	Phase II
Title	Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00094146	Click to show the Detail
Indication	Primary Insulin Hypersecretion; Obesity
Phase	Phase II
Title	Sandostatin LAR? Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
Status	Completed
Sponsor	Novartis
NCT00108355	Click to show the Detail
Indication	Ascites; Cirrhosis
Phase	Phase IV
Title	Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
Status	Completed
Sponsor	US Department of Veterans Affairs
NCT00113360	Click to show the Detail
Indication	Neuroendocrine Carcinoma; Islet Cell Carcinoma
Phase	Phase II
Title	RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Status	Completed
Sponsor	M.D. Anderson Cancer Center
NCT00128232	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Na?ve Acromegalic Patients
Status	Completed
Sponsor	Novartis
NCT00130845	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase III
Title	Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
Status	Completed
Sponsor	Novartis
NCT00131144	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase III
Title	Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
Status	Completed
Sponsor	Novartis
NCT00166725	Click to show the Detail
Indication	Prostate Cancer
Phase	Phase II
Title	Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
Status	Completed
Sponsor	Novartis
NCT00170742	Click to show the Detail
Indication	Proliferative Diabetic Retinopathy
Phase	Phase III
Title	Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Status	Terminated
Sponsor	Novartis
NCT00171613	Click to show the Detail
Indication	Hypothalamic Obesity
Phase	Phase IV
Title	A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
Status	Completed
Sponsor	Novartis
NCT00171873	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase III
Title	Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Status	Completed
Sponsor	Carmen Schade-Brittinger
NCT00171886	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Octreotide Efficacy and Safety in First-line Acromegalic Patients
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00175305	Click to show the Detail
Indication	Hyperphagia; Prader-Willi Syndrome
Phase	Phase III
Title	Prader-Willi Syndrome and Appetite
Status	Terminated
Sponsor	University of British Columbia
NCT00182754	Click to show the Detail
Indication	Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Phase	Phase III
Title	Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Status	Completed
Sponsor	Alliance for Clinical Trials in Oncology
NCT00222092	Click to show the Detail
Indication	Post-ERCP Acute Pancreatitis
Phase	.
Title	Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
Status	Completed
Sponsor	University of Ioannina
NCT00223691	Click to show the Detail
Indication	Autonomic Failure; Orthostatic Hypotension
Phase	Phase I
Title	Treatment of Orthostatic Hypotension in Autonomic Failure
Status	Completed
Sponsor	Vanderbilt University
NCT00225979	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-na?ve Patients With Acromegaly
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00226967	Click to show the Detail
Indication	Breast Cancer
Phase	.
Title	Stress, Diurnal Cortisol, and Breast Cancer Survival
Status	Completed
Sponsor	Stanford University
NCT00227773	Click to show the Detail
Indication	Gastrointestinal Carcinoid Tumor; Islet Cell Carcinoma
Phase	Phase II
Title	Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Status	Withdrawn
Sponsor	Eastern Cooperative Oncology Group
NCT00240045	Click to show the Detail
Indication	Type 2 Hepatorenal Syndrome; Refractory Ascites
Phase	Phase II; Phase III
Title	The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
Status	Completed
Sponsor	University of Alberta
NCT00241020	Click to show the Detail
Indication	Advanced Hepatocellular Carcinoma
Phase	Phase III
Title	Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00242541	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
Status	Terminated
Sponsor	Novartis Pharmaceuticals
NCT00248131	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase III
Title	Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Status	Terminated
Sponsor	Novartis Pharmaceuticals
NCT00248157	Click to show the Detail
Indication	Diabetic Retinopathy
Phase	Phase III
Title	Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Status	Terminated
Sponsor	Novartis Pharmaceuticals
NCT00250796	Click to show the Detail
Indication	Liver; Cancer
Phase	Phase II
Title	Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
Status	Completed
Sponsor	University of New Mexico
NCT00257426	Click to show the Detail
Indication	Liver Cancer
Phase	Phase II
Title	Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Status	Completed
Sponsor	UNC Lineberger Comprehensive Cancer Center
NCT00262470	Click to show the Detail
Indication	Tachycardia; Chronic Orthostatic Intolerance
Phase	Phase I; Phase II
Title	Treatment of Orthostatic Intolerance
Status	Active, not recruiting
Sponsor	Satish R. Raj
NCT00274170	Click to show the Detail
Indication	Migraine Headache
Phase	Phase I; Phase II
Title	Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache
Status	Unknown
Sponsor	C.R.Darnall Army Medical Center
NCT00332696	Click to show the Detail
Indication	Peritoneal Neoplasms; Intestinal Obstruction; Carcinomatosis
Phase	Phase II
Title	Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00332969	Click to show the Detail
Indication	Thymoma
Phase	Phase II
Title	Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00341406	Click to show the Detail
Indication	Obesity
Phase	.
Title	Fat Cell Size in Insulin Resistance
Status	Completed
Sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00363051	Click to show the Detail
Indication	Islet Cell Carcinoma; Neuroendocrine Carcinoma; Neuroendocrine Tumor; Pancreatic Neoplasms
Phase	Phase II
Title	Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00372697	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00376064	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00386984	Click to show the Detail
Indication	Carcinoma, Hepatocellular
Phase	Phase III
Title	Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
Status	Completed
Sponsor	University Hospital Freiburg
NCT00399893	Click to show the Detail
Indication	Prader-Willi Syndrome
Phase	Not Applicable
Title	Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
Status	Terminated
Sponsor	Duke University
NCT00412061	Click to show the Detail
Indication	Carcinoid Tumor; Malignant Carcinoid Syndrome
Phase	Phase III
Title	Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00426153	Click to show the Detail
Indication	Polycystic Kidney, Autosomal Dominant; Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Kidney, Polycystic; Abdominal Pain
Phase	Phase II; Phase III
Title	Octreotide in Severe Polycystic Liver Disease
Status	Completed
Sponsor	Mayo Clinic
NCT00427349	Click to show the Detail
Indication	Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
Phase	Phase II
Title	AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Status	Completed
Sponsor	Eastern Cooperative Oncology Group
NCT00432068	Click to show the Detail
Indication	Healthy Cholecystectomized
Phase	Phase I
Title	Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00461149	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
Status	Completed
Sponsor	Federico II University
NCT00463983	Click to show the Detail
Indication	Idiopathic Pulmonary Fibrosis
Phase	Phase I; Phase II
Title	Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
Status	Completed
Sponsor	Institut National de la Sant Et de la Recherche Mdicale, France
NCT00466856	Click to show the Detail
Indication	Head and Neck Cancer; Islet Cell Tumor; Metastatic Cancer; Pheochromocytoma
Phase	Phase II
Title	Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Status	Terminated
Sponsor	Vanderbilt-Ingram Cancer Center
NCT00510224	Click to show the Detail
Indication	Prostate Cancer
Phase	Phase II
Title	Sandostatin for Patients With Androgen Independent Prostate Cancer
Status	Terminated
Sponsor	University of California, San Francisco
NCT00521300	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Preoperative Octreotide Treatment of Acromegaly
Status	Completed
Sponsor	St. Olavs Hospital
NCT00534677	Click to show the Detail
Indication	Portal Hypertension; Cirrhosis; Hematemesis; Melena
Phase	Phase IV
Title	The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
Status	Completed
Sponsor	Aga Khan University
NCT00552071	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Ultrasound Guided Octreotide LAR Injection in Acromegaly
Status	Completed
Sponsor	Cedars-Sinai Medical Center
NCT00569127	Click to show the Detail
Indication	Atypical Carcinoid Tumor; Carcinoid Tumor; Colorectal Neuroendocrine Tumor G1; Gastric Neuroendocrine Tumor G1; Neuroendocrine Neoplasm
Phase	Phase III
Title	Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Status	Active, not recruiting
Sponsor	National Cancer Institute (NCI)
NCT00582426	Click to show the Detail
Indication	Chemotherapy-induced Diarrhea
Phase	Phase III
Title	Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00595140	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Acute Application of Pegvisomant and Octreotide in Acromegaly
Status	Completed
Sponsor	Ludwig-Maximilians-University of Munich
NCT00600886	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00616408	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Prediction of Tumor Shrinkage in Acromegaly
Status	Completed
Sponsor	Federico II University
NCT00616551	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
Status	Completed
Sponsor	Ambrilia Biopharma Inc
NCT00690430	Click to show the Detail
Indication	Symptomatic Refractory Resistant Carcinoid Disease
Phase	Phase III
Title	Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT00742339	Click to show the Detail
Indication	Cirrhosis; Hepatorenal Syndrome
Phase	Phase II; Phase III
Title	Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
Status	Terminated
Sponsor	University of Padova
NCT00765323	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Status	Terminated
Sponsor	Endo Pharmaceuticals
NCT00781911	Click to show the Detail
Indication	Carcinoma; Neuroendocrine Tumors
Phase	Phase II
Title	A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Status	Completed
Sponsor	Eli Lilly and Company
NCT00789841	Click to show the Detail
Indication	Neuroendocrine Tumor
Phase	.
Title	Gastrointestinal Motility in Patients With Neuroendocrine Tumors
Status	Completed
Sponsor	University of Aarhus
NCT00804297	Click to show the Detail
Indication	Hypoglycemia; Diabetes Mellitus
Phase	Phase III
Title	Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia
Status	Completed
Sponsor	Albert Einstein Healthcare Network
NCT00853047	Click to show the Detail
Indication	Carcinoid Syndrome
Phase	Phase II
Title	Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Status	Completed
Sponsor	Lexicon Pharmaceuticals
NCT00884715	Click to show the Detail
Indication	Carcinoid Syndrome
Phase	Phase I; Phase II
Title	Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Status	Terminated
Sponsor	Endo Pharmaceuticals
NCT00913055	Click to show the Detail
Indication	Acromegaly
Phase	Phase II
Title	Open Label Study of Octreotide Implant in Patients With Acromegaly
Status	Completed
Sponsor	Endo Pharmaceuticals
NCT00953394	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase II
Title	5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
Status	Completed
Sponsor	University of Turin, Italy
NCT00966355	Click to show the Detail
Indication	Variceal Bleeding, Cirrhosis
Phase	Phase IV
Title	Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
Status	Completed
Sponsor	Korea University
NCT00987168	Click to show the Detail
Indication	Congenital Hyperinsulinism
Phase	Phase II
Title	Sandostatine? LP and Hyperinsulinism
Status	Completed
Sponsor	Assistance Publique-H?pitaux de Paris
NCT00990535	Click to show the Detail
Indication	Respiratory Tract Neoplasms; Thymic Neoplasms; Pancreatic Neoplasms; Gastrointestinal Neoplasms; Multiple Endocrine Neoplasia
Phase	Phase II
Title	High Dose Somatostatin Analogues in Neuroendocrine Tumors
Status	Completed
Sponsor	Federico II University
NCT01029275	Click to show the Detail
Indication	Acromegaly
Phase	Not Applicable
Title	Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
Status	Completed
Sponsor	University Hospital, Rouen
NCT01086982	Click to show the Detail
Indication	Acromegaly
Phase	Phase I
Title	Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ? (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A.
Status	Suspended
Sponsor	Azidus Brasil
NCT01121939	Click to show the Detail
Indication	Neuroendocrine Carcinoma
Phase	Phase II
Title	Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Status	Completed
Sponsor	SCRI Development Innovations, LLC
NCT01157858	Click to show the Detail
Indication	Polycystic Liver Disease
Phase	Phase II
Title	Everolimus and LongActing Octreotide Trial in Polycystic Livers
Status	Completed
Sponsor	Radboud University
NCT01188733	Click to show the Detail
Indication	Cirrhosis; Portal Hypertension; Esophageal Varices
Phase	Phase I; Phase II
Title	Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
Status	Completed
Sponsor	Mayo Clinic
NCT01203306	Click to show the Detail
Indication	Neuroendocrine Carcinomas
Phase	Phase II
Title	Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Status	Unknown
Sponsor	University of Turin, Italy
NCT01204476	Click to show the Detail
Indication	Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Paraganglioma; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Merkel Cell Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor; Stage III Merkel Cell Carcinoma; Stage IV Merkel Cell Carcinoma; Thyroid Gland Medullary Carcinoma
Phase	Phase I
Title	Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Status	Completed
Sponsor	National Cancer Institute (NCI)
NCT01229943	Click to show the Detail
Indication	Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Pancreatic Neuroendocrine Tumor; Pancreatic Gastrinoma; Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2; Pancreatic Vipoma
Phase	Phase II
Title	Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Status	Active, not recruiting
Sponsor	National Cancer Institute (NCI)
NCT01278342	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01295060	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
Status	Terminated
Sponsor	Endo Pharmaceuticals
NCT01301222	Click to show the Detail
Indication	Pancreatic Fistula
Phase	Phase IV
Title	Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas
Status	Completed
Sponsor	PVS Memorial Hospital
NCT01324895	Click to show the Detail
Indication	Small Intestinal Bacterial Overgrowth Syndrome (SIBO); Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
Phase	.
Title	Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing
Status	Completed
Sponsor	University of Florida
NCT01346098	Click to show the Detail
Indication	Postpancreatectomy Hyperglycemia
Phase	Phase II
Title	Islet Autotransplantation in Patients at Very High-risk Pancreatic Anastomosis
Status	Completed
Sponsor	Ospedale San Raffaele
NCT01370161	Click to show the Detail
Indication	Decompensated Cirrhosis; Bleeding Varices
Phase	Not Applicable
Title	Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
Status	Completed
Sponsor	Air Force Military Medical University, China
NCT01371643	Click to show the Detail
Indication	Pituitary Adenoma
Phase	Phase IV
Title	Surgical Debulking of Pituitary Adenomas
Status	Completed
Sponsor	NYU Langone Health
NCT01377246	Click to show the Detail
Indication	Autosomal Dominant Polycystic Kidney Disease
Phase	Phase III
Title	Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
Status	Completed
Sponsor	Mario Negri Institute for Pharmacological Research
NCT01400100	Click to show the Detail
Indication	Pancreatic Fistula
Phase	Not Applicable
Title	Effects of Intraarterial Octreotide on Pancreatic Texture
Status	Completed
Sponsor	St. Josef Hospital Bochum
NCT01412424	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Safety of Octreotide (MYCAPSSA? [Formerly Octreolin?]) for Acromegaly
Status	Completed
Sponsor	Chiasma Inc
NCT01424241	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Effects of Sandostatin LAR? in Acromegaly
Status	Unknown
Sponsor	Columbia University
NCT01469338	Click to show the Detail
Indication	Diarrhea; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Phase	Phase II
Title	Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
Status	Terminated
Sponsor	University of Southern California
NCT01480986	Click to show the Detail
Indication	Progression Free Survival of the Treatment
Phase	Phase II
Title	IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC
Status	Completed
Sponsor	Peking University
NCT01561066	Click to show the Detail
Indication	Enterocutaneous Fistulas; Intra-abdominal Infection
Phase	Phase I
Title	Autologous Fibrin Glues for Fistulas Closure
Status	Completed
Sponsor	Jinling Hospital, China
NCT01567488	Click to show the Detail
Indication	Gastrointestinal Neoplasms
Phase	Phase II
Title	Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
Status	Completed
Sponsor	Grupo Espanol de Tumores Neuroendocrinos
NCT01578239	Click to show the Detail
Indication	Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Phase	Phase III
Title	A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Status	Completed
Sponsor	Advanced Accelerator Applications
NCT01587222	Click to show the Detail
Indication	Fibrosis; Renal Failure; Hepatorenal Syndrome
Phase	Phase II
Title	Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure
Status	Withdrawn
Sponsor	Anna Cruceta
NCT01613495	Click to show the Detail
Indication	Prader Willis Syndrome
Phase	Not Applicable
Title	Ghrelin Suppression by Octreotide in Prader-Willi
Status	Active, not recruiting
Sponsor	Oregon Health and Science University
NCT01618513	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
Status	Completed
Sponsor	University of Aarhus
NCT01639352	Click to show the Detail
Indication	Hepatocellular Carcinoma
Phase	Phase II
Title	Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Status	Completed
Sponsor	Lynn Feun
NCT01707225	Click to show the Detail
Indication	Gastrointestinal Bleeding
Phase	Phase I
Title	Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)
Status	Completed
Sponsor	Virginia Commonwealth University
NCT01729169	Click to show the Detail
Indication	Sarcoidosis; Cardiac Sarcoidosis
Phase	.
Title	Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET
Status	Completed
Sponsor	Lars Christian Gormsen
NCT01744249	Click to show the Detail
Indication	Neuroendocrine Tumors; Advanced Cancer
Phase	Phase II; Phase III
Title	Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Status	Active, not recruiting
Sponsor	Grupo Espanol de Tumores Neuroendocrinos
NCT01783899	Click to show the Detail
Indication	Variceal Hemorrhage
Phase	Not Applicable
Title	Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding
Status	Completed
Sponsor	Theodor Bilharz Research Institute
NCT01789281	Click to show the Detail
Indication	Neoplasms
Phase	Phase IV
Title	Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01865760	Click to show the Detail
Indication	Obesity; Hypoglycemia; Surgery
Phase	Not Applicable
Title	Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia
Status	Completed
Sponsor	University of Aarhus
NCT01869725	Click to show the Detail
Indication	Adult Medulloblastoma; Childhood Medulloblastoma; Neuroblastoma; Neuroendocrine Tumor; Somatostatinoma
Phase	Phase II
Title	Ga-DOTATOC Versus Octreoscan + CT
Status	Completed
Sponsor	Sue O'Dorisio
NCT01871844	Click to show the Detail
Indication	Healthy Male Volunteers
Phase	Phase I
Title	ITF2984 Repeated Doses Study in Healthy Volunteers
Status	Completed
Sponsor	Italfarmaco
NCT01886287	Click to show the Detail
Indication	Neuroendocrine Carcinoma
Phase	Phase II
Title	P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Status	Terminated
Sponsor	H. Lee Moffitt Cancer Center and Research Institute
NCT01917773	Click to show the Detail
Indication	Colonic Motility Index; Constipation
Phase	Phase IV
Title	Effect of Octreotide on the Colonic Motility in Pediatric Patients
Status	Completed
Sponsor	Indiana University
NCT02010385	Click to show the Detail
Indication	Roux-en-Y Bariatric Surgery
Phase	Not Applicable
Title	Investigation of the Effects of Obesity Surgery on Appetitive Behaviour
Status	Unknown
Sponsor	University College Dublin
NCT02019706	Click to show the Detail
Indication	ACTH; Cushing's Syndrome
Phase	Phase I; Phase II
Title	Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome
Status	Recruiting
Sponsor	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT02032784	Click to show the Detail
Indication	Adenoma
Phase	Phase IV
Title	Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
Status	Terminated
Sponsor	AdventHealth
NCT02111044	Click to show the Detail
Indication	Acromegaly
Phase	Phase II
Title	Phase II Study With ITF2984 in Acromegalic Patients
Status	Completed
Sponsor	Italfarmaco
NCT02119884	Click to show the Detail
Indication	Gastric and Esophageal Varices
Phase	Phase IV
Title	Hemodynamic Effects of Terlipressin and High Dose Octreotide
Status	Completed
Sponsor	Shanghai Zhongshan Hospital
NCT02194452	Click to show the Detail
Indication	Acoustic Schwannoma; Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Craniopharyngioma; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Myxopapillary Ependymoma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Subependymal Giant Cell Astrocytoma; Adult Subependymoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Childhood Choroid Plexus Tumor; Childhood Craniopharyngioma; Childhood Ependymoblastoma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Infratentorial Ependymoma; Childhood Low-grade Cerebellar Astrocytoma; Childhood Low-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Childhood Supratentorial Ependymoma; Meningeal Melanocytoma; Newly Diagnosed Childhood Ependymoma; Recurrent Adult Brain Tumor; Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Diffuse Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Fibrillary Astrocytoma; Recurrent Childhood Gemistocytic Astrocytoma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Oligoastrocytoma; Recurrent Childhood Oligodendroglioma; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Childhood Pilomyxoid Astrocytoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Pleomorphic Xanthoastrocytoma; Recurrent Childhood Protoplasmic Astrocytoma; Recurrent Childhood Subependymal Giant Cell Astrocytoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Anaplastic Oligodendroglioma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebellar Astrocytoma; Untreated Childhood Cerebral Astrocytoma; Untreated Childhood Diffuse Astrocytoma; Untreated Childhood Fibrillary Astrocytoma; Untreated Childhood Gemistocytic Astrocytoma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliomatosis Cerebri; Untreated Childhood Gliosarcoma; Untreated Childhood Medulloblastoma; Untreated Childhood Oligoastrocytoma; Untreated Childhood Oligodendroglioma; Untreated Childhood Pilocytic Astrocytoma; Untreated Childhood Pilomyxoid Astrocytoma; Untreated Childhood Pineoblastoma; Untreated Childhood Pleomorphic Xanthoastrocytoma; Untreated Childhood Protoplasmic Astrocytoma; Untreated Childhood Subependymal Giant Cell Astrocytoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor; Untreated Childhood Visual Pathway and Hypothalamic Glioma; Untreated Childhood Visual Pathway Glioma
Phase	Not Applicable
Title	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Status	Withdrawn
Sponsor	Sue O'Dorisio
NCT02195635	Click to show the Detail
Indication	Drug Interactions
Phase	Phase I
Title	Phase I, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
Status	Completed
Sponsor	Lexicon Pharmaceuticals
NCT02217800	Click to show the Detail
Indication	Acromegaly
Phase	Phase II
Title	The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
Status	Completed
Sponsor	Aspireo Pharmaceuticals Limited
NCT02217826	Click to show the Detail
Indication	Healthy
Phase	Phase I
Title	Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
Status	Completed
Sponsor	Aspireo Pharmaceuticals Limited
NCT02217839	Click to show the Detail
Indication	Healthy
Phase	Phase I
Title	Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173
Status	Completed
Sponsor	Aspireo Pharmaceuticals Limited
NCT02235987	Click to show the Detail
Indication	Acromegaly
Phase	Phase II
Title	Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
Status	Completed
Sponsor	Aspireo Pharmaceuticals Limited
NCT02237053	Click to show the Detail
Indication	Hyperglucagonemia; Obesity
Phase	Phase I
Title	Effects of Glucagon Administration on Energy Expenditure
Status	Completed
Sponsor	Translational Research Institute for Metabolism and Diabetes, Florida
NCT02294006	Click to show the Detail
Indication	Well Differentiated Pancreatic Endocrine Tumor
Phase	Phase II
Title	Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
Status	Recruiting
Sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT02294786	Click to show the Detail
Indication	Cancer
Phase	Phase II
Title	Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Status	Terminated
Sponsor	Novartis Pharmaceuticals
NCT02299089	Click to show the Detail
Indication	Acromegaly; Neuroendocrine Tumors
Phase	Phase II
Title	Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Status	Completed
Sponsor	Camurus AB
NCT02305069	Click to show the Detail
Indication	Obesity; Sarcopenia
Phase	Not Applicable
Title	Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle
Status	Completed
Sponsor	University of Nottingham
NCT02311608	Click to show the Detail
Indication	Liver Cirrhosis; Esophageal and Gastric Varices; Hemorrhage
Phase	.
Title	Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails
Status	Unknown
Sponsor	Shanghai Zhongshan Hospital
NCT02333565	Click to show the Detail
Indication	Recurrent Meningiomas; Resistant Meningiomas
Phase	Phase II
Title	Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
Status	Unknown
Sponsor	Assistance Publique Hopitaux De Marseille
NCT02374632	Click to show the Detail
Indication	Bariatric Surgery (Gastric Bypass); Severe Obesity
Phase	Phase IV
Title	Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass
Status	Unknown
Sponsor	Hvidovre University Hospital
NCT02381249	Click to show the Detail
Indication	Esophageal Neoplasms; Stomach Neoplasms; Weight Loss; Malnutrition; Pancreatic Neoplasms; Duodenal Neoplasms
Phase	Not Applicable
Title	The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
Status	Completed
Sponsor	St. James's Hospital, Ireland
NCT02384122	Click to show the Detail
Indication	Angiodysplasia; Vascular Malformations; Gastrointestinal Hemorrhage; Anemia
Phase	Phase II; Phase III
Title	Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias
Status	Unknown
Sponsor	Radboud University
NCT02385617	Click to show the Detail
Indication	Esophageal Neoplasms; Stomach Neoplasms; Weight Loss; Malnutrition
Phase	Not Applicable
Title	Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
Status	Completed
Sponsor	St. James's Hospital, Ireland
NCT02409849	Click to show the Detail
Indication	Gastro-entero-pancreatic Carcinoma; Esophageal Neuroendocrine Carcinoma
Phase	Phase II
Title	Octreotide LAR as Maintenance Treatment for Patients With NEC
Status	Unknown
Sponsor	Peking University
NCT02427295	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
Status	Unknown
Sponsor	Asan Medical Center
NCT02437825	Click to show the Detail
Indication	Fistula; Salivary Duct or Gland
Phase	Phase II
Title	Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery
Status	Unknown
Sponsor	Hadassah Medical Organization
NCT02441088	Click to show the Detail
Indication	Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma; Medulloblastoma
Phase	Phase II
Title	Theranostics: 68GaDOTATOC and 90YDOTATOC
Status	Unknown
Sponsor	Sue O'Dorisio
NCT02457156	Click to show the Detail
Indication	Pancreatic Cancer
Phase	Phase III
Title	Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy
Status	Active, not recruiting
Sponsor	University of Liverpool
NCT02474914	Click to show the Detail
Indication	Periampullary Carcinoma Resectable
Phase	Not Applicable
Title	Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy
Status	Completed
Sponsor	Mansoura University
NCT02621541	Click to show the Detail
Indication	Diagnosis
Phase	Phase IV
Title	Nonfunctional Pancreatic NET and PET Imaging
Status	Unknown
Sponsor	Turku University Hospital
NCT02668588	Click to show the Detail
Indication	Seroma
Phase	Phase II
Title	Extended-release of Octreotide (LF-PB) for the Treatment of Seroma
Status	Completed
Sponsor	Chemi S.p.A.
NCT02691078	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase II
Title	Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Status	Completed
Sponsor	Latin American Cooperative Oncology Group
NCT02759718	Click to show the Detail
Indication	Non Functioning Pancreatic Endocrine Tumor
Phase	Phase IV
Title	Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors
Status	Unknown
Sponsor	Asan Medical Center
NCT02874326	Click to show the Detail
Indication	Hereditary Hemorrhagic Telangiectasia; Gastrointestinal Hemorrhage; Anemia
Phase	Phase II
Title	Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
Status	Unknown
Sponsor	Radboud University
NCT02916433	Click to show the Detail
Indication	Octreotide; Sputum
Phase	Phase II
Title	Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients
Status	Completed
Sponsor	Danbury Hospital
NCT02920567	Click to show the Detail
Indication	Periampullary Tumors
Phase	Not Applicable
Title	Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion
Status	Unknown
Sponsor	Saint Vincent's Hospital, Korea
NCT02937935	Click to show the Detail
Indication	Acute Kidney Injury With Cirrhosis
Phase	Not Applicable
Title	On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis
Status	Unknown
Sponsor	Institute of Liver and Biliary Sciences, India
NCT02977897	Click to show the Detail
Indication	Diarrhea; Immunosuppression
Phase	.
Title	Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide
Status	Unknown
Sponsor	University Health Network, Toronto
NCT03000946	Click to show the Detail
Indication	Pancreatic Surgery
Phase	Phase III
Title	Prevention of Postoperative Pancreatic Fistula by Somatostatin
Status	Completed
Sponsor	Assistance Publique-H?pitaux de Paris
NCT03031535	Click to show the Detail
Indication	Healthy Volunteer Study
Phase	Phase I
Title	Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
Status	Completed
Sponsor	Dauntless Pharmaceuticals
NCT03044977	Click to show the Detail
Indication	Neuroendocrine Tumor, Malignant; Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Phase	Phase I
Title	Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Status	Active, not recruiting
Sponsor	David Bushnell
NCT03057509	Click to show the Detail
Indication	Small Bowel Carcinoid Tumor
Phase	Phase I
Title	A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Status	Withdrawn
Sponsor	Massachusetts General Hospital
NCT03061604	Click to show the Detail
Indication	Variceal Hemorrhage
Phase	Not Applicable
Title	RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding
Status	Completed
Sponsor	Theodor Bilharz Research Institute
NCT03158090	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
Status	Recruiting
Sponsor	Ginkgo Leaf Center for Rare Disorders
NCT03179995	Click to show the Detail
Indication	Major Liver Resection
Phase	Phase II
Title	Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
Status	Active, not recruiting
Sponsor	Fox Chase Cancer Center
NCT03252353	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Status	Active, not recruiting
Sponsor	Chiasma Inc
NCT03363581	Click to show the Detail
Indication	Obesity
Phase	.
Title	Food Preference Following Bariatric Surgery
Status	Active, not recruiting
Sponsor	Imperial College London
NCT03377660	Click to show the Detail
Indication	Esophageal Cancer; Weight Gain; Eating Behavior; Food Reward
Phase	.
Title	Resection of the Esophagus and Subsequent Weight Loss
Status	Recruiting
Sponsor	Imperial College London
NCT03398941	Click to show the Detail
Indication	Pancreatic Diseases
Phase	Not Applicable
Title	The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial
Status	Unknown
Sponsor	Chengfeng Wang
NCT03455322	Click to show the Detail
Indication	Renal Impairment in Hepatorenal Syndrome
Phase	Phase IV
Title	Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.
Status	Completed
Sponsor	National Hepatology & Tropical Medicine Research Institute
NCT03511768	Click to show the Detail
Indication	Neuroendocrine Neoplasm
Phase	Phase I; Phase II
Title	A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
Status	Unknown
Sponsor	Xiangya Hospital of Central South University
NCT03520569	Click to show the Detail
Indication	Vascular Stiffness; Insulin Sensitivity
Phase	Phase I
Title	Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
Status	Recruiting
Sponsor	University of Virginia
NCT03541447	Click to show the Detail
Indication	Autosomal Dominant Polycystic Kidney Disease
Phase	Phase II
Title	Tolvaptan-Octreotide LAR Combination in ADPKD
Status	Recruiting
Sponsor	Mario Negri Institute for Pharmacological Research
NCT03571594	Click to show the Detail
Indication	Acromegaly
Phase	Phase I
Title	A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
Status	Terminated
Sponsor	Ono Pharmaceutical
NCT03624517	Click to show the Detail
Indication	Esophageal Varices; Liver Cirrhoses; Bleeding Esophageal Varices; Upper Gastrointestinal Bleeding
Phase	Phase IV
Title	Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
Status	Recruiting
Sponsor	Medical University of South Carolina
NCT03734627	Click to show the Detail
Indication	Esophageal Cancer; Nutrition Disorders; Appetite Disorders; Dumping Syndrome; Delayed Gastric Emptying; Surgery
Phase	.
Title	Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
Status	Enrolling by invitation
Sponsor	St. James's Hospital, Ireland
NCT03756116	Click to show the Detail
Indication	Post-ERCP Acute Pancreatitis; Epinephrine
Phase	Not Applicable
Title	Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
Status	Unknown
Sponsor	The Second Hospital of Nanjing Medical University
NCT03791736	Click to show the Detail
Indication	Breast Cancer; Lymphocele
Phase	Not Applicable
Title	Evaluation of Impact of Sandostatin? Injection Before Axillary Clearance on Lymphocele Formation
Status	Terminated
Sponsor	Institut Cancerologie de l'Ouest
NCT03798912	Click to show the Detail
Indication	Healthy Volunteers
Phase	Phase I
Title	A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform
Status	Completed
Sponsor	RANI Therapeutics
NCT03812939	Click to show the Detail
Indication	Gastric NET
Phase	.
Title	Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
Status	Unknown
Sponsor	Peking Union Medical College Hospital
NCT03846180	Click to show the Detail
Indication	Variceal Hemorrhage; Cirrhosis, Liver; Kidney Injury
Phase	.
Title	Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage
Status	Completed
Sponsor	General Hospital of Shenyang Military Region
NCT03879694	Click to show the Detail
Indication	Lung Atypical Carcinoid Tumor; Lung Typical Carcinoid Tumor; Metastatic Pancreatic Neuroendocrine Tumor
Phase	Phase I
Title	Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Status	Recruiting
Sponsor	Roswell Park Cancer Institute
NCT03883776	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase I
Title	Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
Status	Completed
Sponsor	Universitaire Ziekenhuizen Leuven
NCT03891849	Click to show the Detail
Indication	Haemorrhagic Shock; Variceal Hemorrhage
Phase	Not Applicable
Title	Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock
Status	Recruiting
Sponsor	Centre Hospitalier Universitaire, Amiens
NCT03972488	Click to show the Detail
Indication	Gastro-enteropancreatic Neuroendocrine Tumor
Phase	Phase III
Title	Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Status	Recruiting
Sponsor	Advanced Accelerator Applications
NCT04027348	Click to show the Detail
Indication	Malignant Bowel Obstruction
Phase	Phase II
Title	Palliative Management of Inoperable Malignant Bowel Obstruction
Status	Recruiting
Sponsor	Roswell Park Cancer Institute
NCT04028323	Click to show the Detail
Indication	Renal Function Disorder; Acute Variceal Bleeding
Phase	Phase IV
Title	Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)
Status	Unknown
Sponsor	Nanfang Hospital of Southern Medical University
NCT04048707	Click to show the Detail
Indication	Hepatorenal Syndrome; Cirrhosis; Kidney Failure, Acute
Phase	Phase II
Title	Angiotensin 2 for Hepatorenal Syndrome
Status	Not Recruiting
Sponsor	University of California, Los Angeles
NCT04076462	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Status	Recruiting
Sponsor	Camurus AB
NCT04125836	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Status	Recruiting
Sponsor	Camurus AB
NCT04129255	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase II
Title	Octreotide LAR in the Induction of Immunologic Response in NENs Patients
Status	Completed
Sponsor	National Cancer Institute, Naples
NCT04140409	Click to show the Detail
Indication	Neuroendocrine Tumors; Carcinoid Syndrome
Phase	Phase IV
Title	Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
Status	Terminated
Sponsor	Cliniques universitaires Saint-Luc- Universit Catholique de Louvain
NCT04296149	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase II
Title	Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe
Status	Completed
Sponsor	European Institute of Oncology
NCT04353193	Click to show the Detail
Indication	Liver Cirrhosis Portal
Phase	Phase IV
Title	Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
Status	Not Recruiting
Sponsor	Juan A. Arnaiz
NCT04522297	Click to show the Detail
Indication	Hepato-Renal Syndrome
Phase	Not Applicable
Title	Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome
Status	Completed
Sponsor	National Hepatology & Tropical Medicine Research Institute
NCT04552847	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase II; Phase III
Title	Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
Status	Recruiting
Sponsor	Universitaire Ziekenhuizen Leuven
NCT04790708	Click to show the Detail
Indication	Neuroendocrine Tumors; Peptide Receptor Radionuclide Therapy (PRRT)
Phase	Not Applicable
Title	Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase II)
Status	Recruiting
Sponsor	University Hospital of Ferrara
NCT04871204	Click to show the Detail
Indication	Esophageal Cancer; Gastric Cancer
Phase	Phase II
Title	Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients With Esophageal or Gastric Cancer
Status	Recruiting
Sponsor	Fredrik Klevebro
NCT04917484	Click to show the Detail
Indication	Neuroendocrine Neoplasm
Phase	Phase II
Title	Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
Status	Recruiting
Sponsor	Tine Gregersen, MD
NCT04941911	Click to show the Detail
Indication	Liver Transplantation; Renal Failure
Phase	Phase II
Title	A Feasibility Study of Octreotide Infusion During Liver Transplant.
Status	Not Recruiting
Sponsor	University College, London

References

Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep. 2016 Jan;18(1):7.